HDR monotherapy for locally confined prostate cancer.

HDR monotherapy for locally confined prostate cancer. - HDR-Mono

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038324

Enrollment

Registered

2026-03-23

Start date

2026-03-06

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: HDR brachytherapy, 2 fractions at 1 week intervals, each with a prescribed dose of 13.5 Gy

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with locally confined prostate cancer (cT1-2) • Gleason score 6-7a and =50% positive punch biopsy and PSA =20 ng/ml or Gleason score 7b and =50% positive punch cylinder in biopsy and PSA 10 years • Consent to participate in the study

Exclusion criteria

Exclusion criteria: • Local pre-treatment of prostate cancer (e.g. HiFU) • TURP within the last 6 months • Lithotomy position/anaesthesia not possible • Implantation impaired by the pubic arch • Legal incapacity or lack of consent

Design outcomes

Primary

Measure	Time frame
Toxicity/tolerability (side effects according to CTCAE) during therapy and within one year after therapy	—

Secondary

Measure	Time frame
Effectiveness (biochemical control), progression-free survival, overall survival	—

Countries

Germany

Contacts

Public ContactChristian Schulz

UKSH Campus Kiel

Christian.Schulz@uksh.de+49 (0) 431 500 26523

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026